# Delox

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delox

- Industry: Medical Devices & Equipment
- Headquarters: Portugal
- Website: www.delox.pt
- Total disclosed funding: $0.8M
- Latest round: Seed (May 18, 2022)
- Investors on record: 3

## About

Based in Portugal, and founded in 2018, Delox, a spin-off from the Faculty of Science at the University of Lisbon, operates as a bio-decontamination company. The company was founded by its CEO, Fadhil Musa, Fernando Antunes, and João Pires da Silva. In May 2022, Delox raised EUR 0.75 million in venture funding from Bionova Capital, Caixa Capital Risc, and Kiilto Ventures.

Delox offers an antimicrobial technology that provides bio-decontamination solutions designed specifically for use in laboratories, where the risk of contamination is high. The company's products are effective against a wide range of microorganisms, including bacteria, the SARS-CoV-2 virus, and fungi. They are also non-toxic and leave no harmful residues. The firm offers bio-decontamination devices for a wide range of applications that can be used in the health, pharma, and food and beverage industries.

## Funding rounds

- Seed, May 18, 2022, $0.8M — Caixa Capital, Biovance Capital, Kiilto Ventures

## Investors

- Caixa Capital (https://capitalatlas.ai/funds/caixa-capital) — Seed
- Biovance Capital (https://capitalatlas.ai/funds/biovance-capital) — Seed
- Kiilto Ventures — Seed